

UF Decision Report FY06-07



Beneficiary Advisory Panel

14 Jan 2010

Lt Col (Ret) Dave Meade, PharmD, BCPS

Clinical Operations Director, DoD PEC

Nov 08-Nov 09

- **Major classes: 6**
- **Drugs in Major classes: 40**
- **Beneficiaries: 706,921**
- **Annual spend pre-review: \$343,700,000**
- **Estimated 1st year cost avoidance:
\$108,820,554**



Nov 08- Nov 09


- **Evaluations of drugs in already reviewed classes: 16 Miscellaneous actions (BCF & ECF cleanup, PA reviews, Safety reviews, Section 703): 6**
- **Note, the cost avoidance numbers do not reflect the section 703 cost avoidance**




Asthma Inhalers




Steroid/LABA Combo




Steroid/LABA Combo



Steroid/LABA Combo




Short Acting Beta Agonist - All POS




Short Acting Beta Agonist


Mail Order MTF Retail




Short Acting Beta Agonist - Mail




Short Acting Beta Agonist - Retail




Short Acting Beta Agonist - MTF




Inhaled Corticosteroids – All POS



Inhaled Corticosteroids – All POS



Long Acting Beta Agonist – All POS



P&T Action for the Near Future



– **Basel insulins**

- **Justification:**

- **Other insulin products contracted by VA**
- **Inquiry by the field**

– **IV Clotting Factors**

- **Justification:**

- **ARB delay – needed a class**
- **Several products w/o pricing agreement**
 - » **Attempt to get all manf to comply with 703**

– **New drugs in already reviewed classes - 5**



– BPH alpha blockers

- Justification:

- Flomax generic available
- Remove step
- Probable last review – will lose SME in May

– Anti-lipidemic 1 (Lip1)

- Justification:

- Issues with Vytorin/Zetia
- Position for Lipitor going generic
- Review before loss of SME
- 4 years since last review

– New drugs in already reviewed classes ~4



Aug 2010

- **ARBs**
 - **Justification:**
 - **BI terminated telmesartan BPA**
 - **Probable losartan generic available**
 - **JNC 8 should be available**
- **Ophthalmology 1: Antihistamines/NSAIDs**
 - **Growing classes**
 - **Multiple parts used to train new staff**
- **New drugs in already reviewed classes ≤ 4**



– Diabetes

- Oral sulfonylureas
- TZD re-review
- DPP-4
- GLP-1

– Justification:

- » New entrants into later 2 classes
- » TZD due re-review

– New drugs in already reviewed classes



Feb 2011 (very tentative)

- **IBS drug**
 - **Justification:**
 - New entrants
 - Competition
- **Pancreatic Enzymes**
 - **Justification:**
 - Class redefined by required FDA approval
 - Competition
- **New drugs in already reviewed classes**



“spanner in the works”

- **Smoking Cessation – to comply with new requirements**
- **PPI – Safety of preferred agents**
- **Narcotic analgesics – New drugs/problem prone**
- **TIB – Many new agents need to let them establish history for safety**
- **MS drugs – New oral agents and biologic equivalents may make class more competitive**

